Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from BioArctic AB Class B ( ($SE:BIOA.B) ).
BioArctic AB has entered a collaboration and license agreement with Novartis Pharma AG, leveraging its BrainTransporter technology for potential neurodegeneration treatments. The deal includes a $30 million upfront payment, with potential future milestones and royalties, highlighting BioArctic’s strategic positioning in the neurodegenerative treatment market and its potential for further partnerships.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK243.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a Swedish research-based biopharma company that focuses on innovative treatments for neurodegenerative diseases. Known for inventing Leqembi, the first drug proven to slow Alzheimer’s progression, BioArctic collaborates with partners like Eisai for global commercialization. The company also explores treatments for Parkinson’s and ALS, utilizing its proprietary BrainTransporter technology to enhance drug efficacy across the blood-brain barrier.
Average Trading Volume: 184,880
Technical Sentiment Signal: Strong Buy
Current Market Cap: SEK21.35B
See more insights into BIOA.B stock on TipRanks’ Stock Analysis page.